Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific is offering $3.8 billion of senior unsecured notes across four tranches: $1.0 billion 4.215% notes due 2031, $750 million 4.550% notes due 2033, $1.3 billion 4.902% notes due 2036 and $750 million 5.546% notes due 2046. The notes price near par, generating gross proceeds of about $3.80 billion and net proceeds of about $3.76 billion after $25.7 million of underwriting discounts and estimated expenses. Thermo Fisher plans to use the cash mainly to fund the pending Clario acquisition, a clinical trial data business valued at $8.875 billion in cash plus up to $525 million of additional consideration. The company reports preliminary 2025 results showing fourth‑quarter revenue up 7% to $12.21 billion and full‑year revenue up 4% to $44.56 billion, with diluted EPS rising to $5.21 for the quarter and $17.74 for the year. The notes include standard investment‑grade style covenants, optional redemption features, and a change‑of‑control repurchase at 101% of principal.
A holder of common stock has filed a Form 144 notice to sell 400 shares. The planned sale is to be executed through Fidelity Brokerage Services LLC on the NYSE around 02/09/2026, with an aggregate market value listed as 216480.00. Shares outstanding are shown as 375,708,059, giving a sense of the company’s overall size.
The 400 shares to be sold were acquired on 02/28/2024 via restricted stock vesting from the issuer as compensation. The filing also notes that Gianluca Pettiti, at the same address, sold 2,975 common shares on 11/10/2025 for gross proceeds of 1725500.00 during the past three months.
Thermo Fisher Scientific Inc. is launching a multi‑tranche senior notes offering of unsecured senior debt, with each series paying semiannual interest and featuring optional redemption and change‑of‑control repurchase protections. The notes rank equally with other unsecured senior debt and are structurally subordinated to subsidiary obligations.
Thermo Fisher plans to use the net proceeds primarily to fund the cash portion of its pending Clario Holdings acquisition, with any remainder available for general corporate purposes, including other acquisitions, debt repayment, capital spending or share repurchases. The company also reports preliminary 2025 results showing fourth‑quarter revenue of $12.21 billion versus $11.40 billion and diluted EPS of $5.21 versus $4.78, with full‑year revenue of $44.56 billion versus $42.88 billion and EPS of $17.74 versus $16.53.
Thermo Fisher Scientific Inc. furnished an update on its business by announcing financial results for the fiscal quarter and full year ended December 31, 2025. The company released these results through a press release dated January 29, 2026.
The press release containing the detailed quarterly and annual financial information is provided as Exhibit 99.1. This information is treated as "furnished" rather than "filed" under the Securities Exchange Act of 1934, which limits how it is incorporated into other regulatory documents.
Thermo Fisher Scientific Inc. filed a Form 25 to remove its 1.400% Senior Notes due 2026 from listing and registration on the New York Stock Exchange. The exchange states it has followed its own rules to strike this class of debt securities from listing and/or withdraw their registration, and the issuer has complied with the exchange’s procedures and the related SEC requirements for voluntary withdrawal.
Thermo Fisher Scientific Inc. has had its 3.200% Senior Notes due 2026 removed from listing and registration on the New York Stock Exchange LLC. The Exchange certified that it complied with its own rules to strike this class of securities from listing and/or withdraw their registration, and the issuer complied with the Exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) for voluntary withdrawal. This action applies specifically to the 3.200% Senior Notes due 2026 and does not describe any change to the company’s other listed securities.
Thermo Fisher Scientific Inc. reported upcoming leadership changes following the planned departures of two senior executives. Executive Vice President and Chief Operating Officer Michel Lagarde, who has held the COO role since 2021, will leave the company on March 31, 2026. Executive Vice President Frederick M. Lowery, in that role since 2024, will depart on February 28, 2026.
Effective March 1, 2026, the company will update its organizational structure. Marc N. Casper will serve as Chairman and Chief Executive Officer. Gianluca Pettiti, currently an Executive Vice President, will be promoted to President and Chief Operating Officer, while Michael Shafer, also an Executive Vice President, will move into an expanded role reporting directly to the Chief Executive Officer. These changes outline Thermo Fisher’s succession and leadership realignment plan at the top of the organization.
Thermo Fisher Scientific director reports additional deferred stock units. A Thermo Fisher Scientific Inc. (TMO) director filed a Form 4 for a transaction dated 12/31/2025. The filing shows an acquisition of 53.93 phantom stock units, each convertible into one share of common stock, recorded in Table II as a derivative security held directly.
The 53.93 units were credited at a price of $579.45 per unit under the company’s Deferred Compensation Plan for Directors. Under this plan, quarterly director retainers are deferred into common stock units based on the closing stock price at quarter end. The underlying shares are scheduled to be distributed in stock when the director’s service ends for any reason or upon a change of control.
Thermo Fisher Scientific director reports deferred stock units grant
A Thermo Fisher Scientific Inc. director, R. Alexandra Keith, reported an acquisition of 53.93 phantom stock units on December 31, 2025 under the company’s Deferred Compensation Plan for Directors. These units are credited based on the closing stock price at quarter end, which was $579.45 per unit, and each unit is convertible into one share of common stock. Following this transaction, the director beneficially owns 1,204.42 phantom stock units, which will be distributed in stock after the director’s service ends or if there is a change of control.
Thermo Fisher Scientific director reports deferred stock units under incentive plan. A reporting person serving as a director of Thermo Fisher Scientific Inc. (TMO) disclosed a routine change in holdings through a Form 4 filing. On December 31, 2025, the director received 73.35 phantom stock units, each convertible into one share of common stock, under the company’s Deferred Compensation Plan for Directors.
The units were credited at a price of $579.45 per unit, based on the closing stock price at quarter end, bringing the director’s total derivative holdings to 17,502.02 stock units held directly. These stock units are designed to mirror common stock and are distributable in shares when the director’s service ends or upon a change of control, aligning director compensation with long‑term shareholder value.